• Skip to main content
  • Skip to after header navigation
  • Skip to site footer
ERN: Emerging Researchers National Conference in STEM

ERN: Emerging Researchers National Conference in STEM

  • About
    • About AAAS
    • About NSF
    • About the Conference
    • Project Team
    • Advisory Board
  • Conference
  • Abstracts
    • Abstract Submission Process
    • Abstract Submission Guidelines
    • Presentation Guidelines
  • Travel Awards
  • Resources
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us
  • Login

Identification of inhibitor for protein arginine methyltransferase 4 (PRMT4) by using computer assisted drug design (CADD)

Undergraduate #2
Discipline: Biological Sciences
Subcategory: Cancer Research

Zoya Anderson - Stillman College
Co-Author(s): Anghesom Ghebremedhin, Ahmad Salam, Clayton Yates, and Balasubramanyam Karanam, Tuskegee University, Tuskegee, AL



Worldwide, breast cancer is the most common cancer observed in women accounting for 25% of all cancers, with 1.7 million new cases diagnosed since 2012. It is one of the leading causes of death among women in the United States. Although Caucasian women are more likely to be diagnosed with the disease, the breast cancer mortality for African American women is about 40% higher than it is for Caucasian women. This is due to the fact that African American women are more likely to be diagnosed with aggressive subtypes of breast cancer. Therefore, novel therapeutic treatment targets need to be discovered and tested. The protein arginine methyltransferases (PRMTs) are a family of enzymes that catalyze arginine methylation and are implicated in a myriad of cellular pathways including transcription, DNA repair, RNA metabolism, signal transduction, protein–protein interactions and subcellular localization. In breast cancer, the expression levels and enzymatic activity of a number of PRMTs are dysregulated; significantly altering the regulation of many cellular pathways that are implicated in breast cancer development and progression. In this study, a novel peptide, termed compound 11, was identified using computer assisted drug discovery against PRMT4. It was hypothesized that this peptide drug would behave as a treatment against aggressive breast cancer by reducing cell viability. The drug was evaluated against an aggressive breast cancer cell line MDA-MB-231 by using in vitro apoptotic assays namely MTT assay, clonogenic assay, and Annexin V staining. Although preliminary, the results indicate that the peptide drug has the potential to serve as a therapeutic treatment for aggressive breast cancer. However, to determine the drug’s full potential, its toxicity will be tested on normal epithelial cells. Also, Western Blot and qPCR analyses will be run to validate the PRMT4 inhibition. Finally, the efficacy of compound 11 will be tested on animal models.

Funder Acknowledgement(s): This research was funded by the National Science Foundation Grant# DMR-1358998.

Faculty Advisor: Balasubramanyam Karanam, bkaranam@mytu.tuskegee.edu

Role: For this research, I performed the assays that evaluated the discovered compound against the aggressive breast cancer cells. I also analyzed and organized the data into graphs and figures.

Sidebar

Abstract Locators

  • Undergraduate Abstract Locator
  • Graduate Abstract Locator

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW
Washington,DC 20005
202-326-6400
Contact Us
About Us

  • LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • YouTube

The World’s Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

Focus Areas

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law

© 2023 American Association for the Advancement of Science